• 011-26907444
  • raghava@iiitd.ac.in

Welcome to Peptide Card of AntiTbPdb

This page displays user query in tabular form.

AYQGVQQKW details
Primary information
ID antitb_1454,
Name25809751
N-Terminal modificationA24-ESAT6
C-Terminal ModificationAYQGVQQKW
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature9
SourceL
SpeciesProtein derived
StrainMTB derived protein ESAT6
Inhibition ConcentrationMycobacterium tuberculosis
In Vitro/ In vivoMycobacterium tuberculosis Rv
Sequence2104
CytotoxicityNA
In vivo ModelNA
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment
Combination TherapyDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy.
Other activitiesCD8+ T-cell
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1728,
NameUS 2002/013197
N-Terminal modificationSEQ ID NO 10
C-Terminal ModificationAYQGVQQKW
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature9
SourceL
SpeciesProtein Derived
StrainFrom the proetins containing mycobacterial CD8 T cell epitopes
Inhibition ConcentrationMycobacterium tuberculosis
In Vitro/ In vivoMycobacterium tuberculosis
Inhibition ConcentrationIn vitro
Sequence2002
CytotoxicityPBMcs
In vivo ModelNA
Lethal DoseNA
Immune Responceβ2-microglobulin gene knowckout mice, TAP-1 null mutant mice and HSP-65 immunized mice
Mechanism of ActionNA
TargetIFN-γ release increases
Combination TherapyBy CD8 T cell response
Other activitiesNA
PMIDNone
Year of PublicationNone
Tertiary Structure
(Technique)
Not Predicted),